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ABSTRACT
Serglycin is an intracellular proteoglycan with a unique ability to adopt highly 
divergent structures by glycosylation with variable types of glycosaminoglycans 
(GAGs) when expressed by different cell types. Serglycin is overexpressed in 
aggressive cancers suggesting its protumorigenic role. In this study, we explored 
the expression of serglycin in human glioma and its correlation with survival and 
immune cell infiltration. We demonstrate that serglycin is expressed in glioma and 
that increased expression predicts poor survival of patients. Analysis of serglycin 
expression in a large cohort of low- and high-grade human glioma samples reveals 
that its expression is grade dependent and is positively correlated with mast cell 
(MC) infiltration. Moreover, serglycin expression in patient-derived glioma cells is 
significantly increased upon MC co-culture. This is also accompanied by increased 
expression of CXCL12, CXCL10, as well as markers of cancer progression, including 
CD44, ZEB1 and vimentin.
In conclusion, these findings indicate the importance of infiltrating MCs in 
glioma by modulating signaling cascades involving serglycin, CD44 and ZEB1. The 
present investigation reveals serglycin as a potential prognostic marker for glioma 
and demonstrates an association with the extent of MC recruitment and glioma 
progression, uncovering potential future therapeutic opportunities for patients.
INTRODUCTION
Glioblastoma (GBM) is one of the most lethal 
human cancers. The majority (~90%) of these tumors 
are classified as primary GBMs that develop rapidly in 
patients without any clinical or histologic evidence of a 
less malignant precursor lesion. A small population of 
younger patients however show incidence of secondary 
GBMs. Even though these two GBM classes display 
similar histologic appearance, primary and secondary 
GBMs have been shown to be distinct tumor entities [1]. 
There is no early detection for primary GBM. The 
widespread tumor cell infiltration makes complete surgical 
excision impossible without damaging vital or eloquent 
structures in the brain. Despite the advances in radiation 
and chemotherapy and the efforts to design new treatment 
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strategies, GBMs invariably recur as aggressive, therapy-
resistant relapses and patients rapidly succumb to these 
tumors. The prognosis for primary GBMs remains among 
the poorest, with a median survival for patients of just over 
one year [2]. 
The essential role of tumor microenvironment 
(TME) in cancer progression has been well documented 
and recent findings indicate that the microenvironmental 
components contribute to the proliferative and migratory 
potential of cancer cells and represent promising 
therapeutic targets and diagnostic markers [3]. For 
instance, the evasiveness of glioma from immune 
responses is considered to involve chronic inflammation 
and recruitment of myeloid suppressor cells, microglia 
and T-regulatory cells that effectively obstruct an anti-
tumor immune response [4]. Nonetheless, the interrelation 
between the immune system and glioma remains 
incompletely understood. 
Mast cells (MCs) are key regulators of the TME, 
affecting angiogenic processes, immune modulation 
and tissue remodeling [5]. The uniqueness of MCs lies 
in their functional plasticity [6]. The life and activity 
of MCs as well as the magnitude and nature of their 
responses to stimulation is regulated and fine-tuned by 
various environmental and genetic factors. The role of 
MCs in cancer is still controversial since depending on 
the type and malignancy grade of the cancer it can be 
either supportive or detrimental for progression and 
establishment for malignant tumors [7]. We previously 
reported that gliomas also contain MCs and we addressed 
the role for different axes in chemotactic infiltration of 
MCs into glioma [8–10].
The GBM microenvironment contains a complex 
mixture of various cell types, extracellular matrix (ECM) 
proteins and glycosaminoglycans (GAGs). Serglycin 
proteoglycan is the dominant proteoglycan species in 
most hematopoietic cells including MCs and it is also 
expressed in non-hematopoietic cells like endothelial cells, 
fibroblasts and certain aggressive cancer cells [11]. In its 
intracellular form its function is related to packaging of 
mediators in storage granules and secretory vesicles. Upon 
secretion serglycin can modulate the activities of binding 
partners by either/or protecting, transporting, activating 
and interacting with target cells or mediators in the ECM 
[11]. Serglycin is the major intracellular proteoglycan 
species in MCs, where it is localized in the granules and 
implicated in the storage of proteases, whereas upon 
activation it is secreted into the extracellular matrix 
along with the proteases. Several studies demonstrated 
that serglycin with different GAG chains and sulfation 
pattern is expressed in numerous human hematopoietic 
and non-hematopoietic tumors [12–14]. Recently it was 
also reported that serglycin expression is essential for 
metastatic growth and dissemination [11]. The role of 
serglycin in malignancies is rather intriguing because it 
appears to mediate interactions between tumor cells and 
TME, suggesting for serglycin to be a modulator within 
the complex tumor “ecosystem” [15, 16].
Here we demonstrate that serglycin is expressed in 
glioma and predicts poor survival of patients. Serglycin 
expression is positively correlated with MC accumulation in 
tissue microarrays (TMAs) of a large cohort of human high-
grade glioma tissues. We show that serglycin can promote 
aggressiveness in glioma by increasing the expression 
of ZEB-1 and vimentin. In addition, the expression of 
serglycin and ZEB-1 is positively correlated in high-grade 
glioma. Further, we provide evidence that MCs can have 
a potential role in serglycin induced tumor progression by 
activating a CD44-related signaling pathway. 
The present investigation reveals serglycin as a 
potential prognostic marker for glioma. It also demonstrates 
the association with the extent of MC recruitment and 
glioma progression, suggesting a functional link between 
serglycin, MCs and glioma malignancy grade.
RESULTS
Serglycin expression in human cancers. 
High serglycin expression in human primary 
glioblastoma correlates with low survival rate
Serglycin has been reported to be overexpressed in 
human cancers [14, 17, 18]. In order to get an overview 
of the extent of SRGN expression in various cancers and 
compare it to GBM patients, we analyzed a large set of 
publicly available expression data in the R2 analysis 
webtool (R2 Genomics and Visualization Platform, 
Oncogenomics, AMC) to explore the landscape of 
SRGN expression patterns across major human cancers 
(prostate, ovary, lung, kidney, endometrium, colon, breast, 
myeloma, hepatocellular carcinoma (HCC), glioblastoma 
(GBM), non-small cell lung carcinoma (NSCLC), 
medulloblastoma (MB), B-cell lymphoma). Indeed we 
found SRGN expression to be high in these cancers with a 
correlation to malignancy grade. 
The analysis also demonstrated high SRGN 
expression in GBM (Figure 1A). In order to assess the 
potential relation of SRGN signaling in human GBM we 
analyzed the TCGA dataset of 540 GBM patient samples 
and found an upregulation of SRGN in these patients. 
We used the well-established markers EGFR and PTEN 
as positive and negative controls for upregulated SRGN 
expression in human GBM. To evaluate a potential 
correlation between the SRGN expression and patient 
survival we analyzed the TCGA GBM dataset for 540 
patients with matching transcriptome and survival data. 
First, we sorted the TCGA patients by SRGN expression 
from high to low and performed a Kaplan-Meier survival 
analysis to compare the top 25% patients (with high 
expression) and the bottom 25% of patients (with low 
expression). This analysis showed a significant difference 
in survival between the two groups (Figure 1B, log-rank 
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p-value = 0.037) with high SRGN expression giving a 
poor prognosis.
Furthermore, a closer statistical analysis revealed 
varied expression levels of SRGN among the different 
GBM subtypes (Supplementary Figure 1). Patient-derived 
glioma cell cultures used in this study are part of the 
Uppsala University Human Glioma Cell Culture (HGCC) 
collection that comprises well characterized GBM-derived 
cell cultures [19]. A survival analysis based on the HGCC 
data (n = 40), although not significant, showed a similar 
tendency of high SRGN expression being associated with 
poor prognosis (data not shown). 
The level of serglycin expression is correlated 
with human glioma malignancy grade. MCs as 
potential modulators of serglycin expression in 
GBM
Although there are studies investigating 
proteoglycans as therapeutic targets in the brain TME [20] 
there is no population-based study of tissue morphology 
and serglycin expression in glioma. We performed tissue 
analysis of serglycin expression in human low-grade 
(astrocytomas, oligoastrocytomas and oligodendrogliomas 
grade II, n = 87) and high-grade glioma (anaplastic 
Figure 1: SRGN is overexpressed in human cancers. High SRGN expression in human glioma correlates with low survival rate. (A) 
Comparison of SRGN expression patterns across major human cancers: prostate (n = 72), ovary (n = 256), lung (n = 121), kidney (n = 261), 
endometrium (n = 209), colon (n = 315), breast (n = 351), myeloma (n = 542), hepatocellular carcinoma (HCC) (n = 91), glioblastoma 
(GBM) (n = 84), non-small cell lung carcinoma (NSCLC) (n = 410), medulloblastoma (MB) (n = 73), B-cell lymphoma (n = 420). All 
clinical data for this analysis was obtained from the R2 genomic analysis platform. (B) Survival analysis comparing GBM patient survival 
with high and low SRGN expression. Log-rank p-value = 0.037 (n = 504). Clinical data for the TCGA patients was obtained from the TCGA 
portal and in each case the maximum value of the survival time available was used. Significant differences in survival between groups were 
evaluated using a Kaplan-Meier analysis with censoring at confidence interval 95%.
Table 1: Human primers used for qPCR
Target gene Forward sequence Reverse sequence
Beta actin GGACTTCGAGCAAGAGATGG AGCACTGTGTTGGCGTACAG
ZEB1 GGCATACACCTACTCAACTACGG TGGGCGGTGTAGAATCAGAGTC
SRGN CGTCTGAGGACTGACCTTTTTCC CGTTAGGAAGCCACTCCCAGAT
Vimentin GTTTCCCCTAAACCGCTAGG GACACGGACCTGGTGGAC
CD44 CCAGAAGGAACAGTGGTTTGGC ACTGTCCTCTGGGCTTGGTGTT
MKI67 GAAAGAGTGGCAACCTGCCTTC GCACCAAGTTTTACTACATCTGCC
CXCL10 GGTGAGAAGAGATGTCTGAATCC GTCCATCCTTGGAAGCACTGCA
CXCL12 CTCAACACTCCAAACTGTGCCC CTCCAGGTACTCCTGAATCCAC
TNF-α CCCATGTTGTAGCAAACCCTC TATCTCTCAGCTCCACGCCA
IL-6 GCCCTGAGAAAGGAGACAT TTGTTTTCTGCCAGTGCCTC
CXCL1 AGCTTGCCTCAATCCTGCATCC TCCTTCAGGAACAGCCACCAGT
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gliomas and glioblastomas, n = 101) TMAs. High-grade 
glioma demonstrated significantly higher expression of 
serglycin in comparison to low-grade glioma (Figure 2). 
The glioma microenvironment has been shown to 
contain varying levels of immune cell infiltration, e.g. of 
MCs, macrophages and T cells [21]. Most of these immune 
cells have serglycin repertoire and MCs have a high 
capacity for serglycin expression as compared with the 
other cell types [22]. To map the immune cell infiltration 
in low- and high-grade gliomas and to investigate potential 
correlation to serglycin expression levels we performed 
immunohistochemistry for CD163+ tumor-associated 
macrophages (TAMs), MCs (tryptase positive) and 
tumor-infiltrating CD3+ and CD8+ lymphocytes (TILs) 
(Figure 3). Previous studies from our lab have shown 
that the number of MCs in human glioma is dependent 
on malignancy grade [9] but their functional contribution 
to tumor progression remains unclear. In the present 
investigation we also found that CD163+ cell numbers 
were significantly higher in the high-grade glioma TMAs 
as compared to the low-grade (Figure 3A). Infiltrating 
CD3+ and CD8+ T cells were very scarce in both low- and 
high-grade glioma tissues and were not abundant as other 
infiltrating cells (Figure 3B). This observation is in line 
with some studies showing that decreased CD3+ and CD8+ 
T cells in advanced glioma is associated with profound 
host immunosuppression [23], whereas others attributed 
these low numbers to the blood brain barrier (BBB) [24].
Statistical analysis of the high-grade glioma TMAs 
for serglycin expression and MC numbers revealed a 
positive correlation (Spearman’s rho (ρ) = 0.2) between 
the number of infiltrating MCs and the relative intensity 
of staining for serglycin (Figure 3C), suggesting that MCs 
can be considered as one of the modulator of serglycin 
expression in GBM.
Co-culture of MCs and glioma cells induces the 
expression of SRGN and CD44 in glioma cells 
and is accompanied by increased expression of a 
distinct set of proinflammatory cytokines in both 
cell types 
Considering the positive correlation between 
MC number and serglycin expression in TMAs and our 
previous studies on MC recruitment to glioma [8–10], we 
postulate that serglycin expression modulated by MCs can 
support glioma progression. In order to study the crosstalk 
between MCs and glioma cells, individual patient-derived 
and well-characterized HGCC cell lines were grown in co-
culture with LAD2 cells.
Considering the variety of receptors and mediators 
expressed by MCs, we were interested in studying the 
bidirectional/mutual induction of mediators between MCs 
and glioma cells.
Analysis of the glioma cell lines after glioma 
cell-mast cell (GC-MC) co-culture at different time-
points indicated an increased SRGN (Figure 4A–4B) 
and CD44 expression (Figure 4C) as compared when 
culturing glioma cells in normal cell culture media. 
CD44, a transmembrane glycoprotein that is involved in 
cell–cell and cell-matrix interactions either through its 
affinity for serglycin, hyaluronic acid (HA), or other ECM 
components, has been shown to be upregulated in various 
cancer types including glioma and increased expression of 
CD44 promotes the metastasizing and migratory potential 
of tumor cells [25]. We postulate that increased expression 
of serglycin, as a main interacting partner for CD44, upon 
co-culture with MCs induces the CD44 expression on 
glioma cells to initiate a bidirectional signaling between 
CD44 and its surroundings. Additionally, serglycin can 
also initiate an autocrine signaling pathway to enhance the 
Figure 2: Serglycin expression is correlated with human glioma malignancy grade. Representative TMA cores of low-grade 
glioma (LGG) (upper left panel) and high-grade glioma (HGG) (upper right panel) for serglycin expression. Selected areas from upper 
panels are magnified in the middle panel. TMAs involved tumor tissue from high-grade gliomas (anaplastic gliomas and glioblastomas, 
n = 101) and gliomas WHO grade II (astrocytomas, oligoastrocytomas and oligodendrogliomas grade II, n = 87). Scale bar = 200 μm. 
Quantification of the SRGN expression levels (lower panel) shows significantly higher level of SRGN expression in the high-grade glioma 
TMA. Data is expressed as mean + SEM values and significance differences are indicated in the figure. **p < 0.01. 
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proliferation and metastasing capacity of the tumor cells 
[26]. Moreover, potential crosstalk between serglycin and 
CD44, may function as an amplifier modulating a variety 
of tumor induction signals [25]. 
Chemokines and their receptors serve as critical 
communication bridges between tumor cells and stromal 
cells to create a microenvironment beneficial for tumor 
development. Their aberrant overexpression in various 
cancers strongly promotes growth and proliferation 
through multiple signaling pathways. A link between 
MCs and the CXCL12 in glioma TME had previously 
been established. In our study, we observe a marked 
increase in the expression of CXCL10 and CXCL12 in 
the glioma cells after co-culture as compared to normal 
culturing of glioma cells (Figure 5A). CXCL12 has been 
reported to be overexpressed in various cancer types 
which, in turn, strongly promotes proliferation, migration 
and invasion [27]. CXCL12 is also a potent chemotactic 
agent for lymphocytes [28, 29] and can induce an increase 
in monocyte-macrophage infiltration into the glioma 
microenvironment [30] MC infiltration in the glioma TME 
leads invariably to a tissue inflammation. Analysis of 
proinflammatory cytokines showed an increase in TNF-α 
expression in the MC co-cultured glioma cells (Figure 5A).
Interestingly, an upregulation of IL-6 and CXCL1 
mRNA in LAD2 cells was observed in response to the co-
culture (Figure 5B). Both cytokines have been associated with 
tumor related inflammation and disease progression [31, 32].
Serglycin can induce aggressiveness and 
propagation in glioma cells
Our finding suggests that glioma cells induce 
expression of specific MC mediators to assist them in 
propagation and establishment of a suitable TME. 
Considering the abundance of serglycin in high-grade 
gliomas and increased serglycin expression in glioma cells 
after GC-MC co-culture, we decided to further analyze 
the high-grade glioma TMAs for potential correlation 
between serglycin expression and markers related to tumor 
aggressiveness. One such marker that was induced in our 
co-cultures, CD44, is widely expressed in glioma, and 
Figure 3: Immune cell infiltration in the glioma microenvironment: MCs as potential modulators of SRGN expression 
in GBM. (A) Immunohistochemical staining for CD163 in human low- and high-grade glioma TMAs. Representative TMA cores of 
low-grade glioma (upper left panel) and high-grade glioma (upper right panel) for CD163 expression. Selected areas from upper panels 
are magnified in the middle panel. TMAs included tumor tissue from high-grade gliomas (anaplastic gliomas and glioblastomas, n = 101) 
and gliomas WHO grade II (astrocytomas, oligoastrocytomas and oligodendrogliomas grade II, n = 87). Quantification of the CD163 
expression levels (lower panel) shows significantly higher CD163 expression in the high-grade glioma TMA compared to the low-grade 
glioma. ***p < 0.001 (B) Immunofluorescence staining for CD3 and CD8 in human glioma TMAs. Representative staining’s for CD3 
(upper left panel), CD8 (upper middle panel) and CD3CD8 with DAPI staining (upper right panel). TMAs included tumor tissue from 
high-grade gliomas (anaplastic gliomas and glioblastomas, n = 101) and gliomas WHO grade II (astrocytomas, oligoastrocytomas and 
oligodendrogliomas grade II, n = 87). Quantification of the CD3 and CD8 expression levels (lower panel) shows no significant difference in 
the CD3+CD8+ cells between the low- and high-grade glioma TMA. Data is expressed as mean values + SEM and significance differences 
are indicated in the figure. ns = not significant. Scale bar = 200 μm  (C) Spearman’s rank correlation analysis between the number of 
infiltrating MCs and serglycin expression level, (Spearman’s rho (ρ) = 0.2). LGG = low-grade glioma, HGG = high-grade glioma. 
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showed strong and widespread cytoplasmic staining in 
immunohistochemistry (data not shown). However, the 
extent of intense and diffuse staining rendered it unsuitable 
for quantification. As CD44 is associated with glioma 
stem cells [33] and recent studies indicate a reciprocal link 
between CD44 and ZEB1 [34] we tested whether ZEB1 may 
be a substitute marker for CD44. ZEB1 is associated with 
malignancy in glioma [35] and analysis of GBM patient 
specimens demonstrated that proinflammatory cytokines, 
such as CXCL12, IGFBP2, IL-1ß, TNF-a and MIF, correlate 
significantly with ZEB1 expression in tumor specimens 
(Supplementary Figure 2). Furthermore, our previous studies 
have shown CXCL12 and MIF secreted from glioma cells 
to be potent chemoattractants for MC recruitment in glioma 
[8, 9]. Indeed, high-grade glioma TMAs immunostaining 
for ZEB1 revealed abundant expression of this protein 
(Figure 6A), as well as a positive correlation between 
ZEB1 and serglycin levels (ρ < 0.01, Figure 6B). We 
further analyzed expression of genes involved in glioma 
progression, to investigate the effect of increased serglycin 
expression in the glioma cells upon GC-MC co-culture. 
As seen in Figure 6C and Supplementary Figure 3, the 
expression of ZEB1 and vimentin as well as Ki-67 (MKI67) 
as proliferation marker, was increased in co-cultured glioma 
cells as compared to glioma cells cultured without LAD2 
cells. This data suggests that serglycin can support and 
further induce progression and propagation of glioma cells.
DISCUSSION
Despite recent therapeutic advances, GBMs remain 
devastating tumors and there is a continuing need for 
improvement in identification and characterization 
of potential prognostic biomarkers. The glioma 
microenvironment is a network of complex interactions 
between diverse cell types, including immune cells, 
fibroblasts, mesenchymal stem cells and endothelia. The 
microenvironment also includes the ECM and the factors 
produced by the host cells as well as the tumor cells. 
A balanced and normal ECM, comprising of proteins, 
glycoproteins and proteoglycans, is important to prevent 
tumor progression and tumor angiogenesis. Hence, recent 
studies have focused largely on evaluating the role of this 
microenvironment in tumor formation and progression [21].
Recent studies have shown overexpression of 
serglycin in several aggressive cancer types, including 
breast cancer, hepatocellular carcinoma, nasopharengeal 
carcinoma and myeloma. Although several recent 
studies have demonstrated the emerging role of serglycin 
in tumorigenesis [15, 18, 36] not much information 
is available on the expression and distribution of 
this proteoglycans in brain tumors. By performing 
bioinformatic analysis for SRGN expression from large 
patient datasets we show significantly elevated SRGN 
levels in various malignant cancers, including GBM. 
Figure 4: MCs can modulate SRGN and CD44 expression in glioma cells upon co-culture. (A) Expression analysis of SRGN 
in the glioma cells after co-culture with LAD2 cells for 24 hours (plain bars) and 48 hours (striped bars) show a significant increase in 
SRGN expression levels at 48 hours. (B) Left panel shows representative pictures of serglycin staining in glioma cells. Left upper panel: 
control glioma cells and left bottom panel: glioma cells after 48 hours co-culture with LAD2 cells. Right panel shows the quantification of 
staining.  Right upper panel: percentage area of serglycin expression, right bottom panel: relative density of serglycin staining (C) qPCR 
analysis for the expression of CD44 in the glioma cells after co-culture with LAD2 cells for 48 hours. Scale bar = 100 μm All the results are 
represented as increase in fold expression compared to the expression levels without co-culture. The experiments were performed 3 times, 
with triplicates in each case. Data is expressed as mean values + SEM and significance differences are indicated in the figure. GC = glioma 
cells, GC+MC = glioma cells co-cultured with LAD2 cells. *p < 0.05, **p < 0.01, ***p < 0.001 versus cells grown without co-culture. 
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The analysis of the TCGA GBM dataset also revealed 
significant upregulation of SRGN. Kaplan-Meier survival 
curves using the TCGA GBM dataset show that high 
SRGN expression results in poor prognosis for GBM 
patients. Histological analysis in our study reveals that 
serglycin is expressed in human glioma and the level of 
expression is increasing with glioma grade. 
We previously demonstrated that recruitment of 
MCs in glioma is dependent on several glioma-secreted 
factors [6–8]. We also found that MC recruitment 
increases with tumor grade. Serglycin is the major 
proteoglycan in MCs and can act as an immune modulator 
in the TME and enhance the resistance of tumor cells to 
various therapeutic agents. The presence of serglycin is 
associated with increased invasion and metastasis of 
tumor cells. Furthermore, its charged GAG moiety makes 
it an ideal binding partner for molecular effectors like 
proteolytic enzymes, chemokines, cytokines and growth 
factors in regulation of their biosynthesis, secretion and 
activity by protecting and accompanying them to specific 
target sites [16]. We examined the infiltration of immune 
cells, particularly CD163+ TAMs, MCs, CD3+ and CD8+ T 
cells, and found significant infiltration of TAMs and MCs 
to high-grade gliomas whereas CD3+ and CD8+ T cell 
infiltration was selective and not widespread. We found 
a positive correlation between MC numbers and serglycin 
expression in human high-grade glioma tissues implying 
MCs as a major serglycin source.
Studies report significantly elevated SRGN 
expression in breast and lung cancer cell lines, as 
compared to colon and gastric cancer cell lines [36]. 
We analyzed the constitutive SRGN expression levels 
in 40 primary HGCC cell lines and found moderate but 
variable expression levels. To evaluate the effect of MCs 
on glioma cells and their combined effect on the ECM, 
co-culture analysis was performed. We found that SRGN 
is overexpressed in GBM cells upon interaction with 
MCs and that secreted serglycin can thereby stimulate 
Figure 5: Increased SRGN expression is accompanied by increased expression of a distinct set of mediators in both 
glioma cells and MCs. (A) qPCR analysis for the expression of CXCL10, CXCL12 and TNF-α in the glioma cells after co-culture with 
LAD2 cells for 48 hours show a significant increase in expression in the co-cultured glioma cells as compared to not co-culturing with 
LAD2 cells. (B) qPCR analysis for the expression of CXCL1 and IL-6 in the LAD2 cells after co-culture with the glioma cells for 48 hours 
show a significant increase in expression in the co-cultured LAD2 cells as compared to not co-culturing with glioma cells. All the results are 
represented as increase in fold expression compared to the expression levels without co-culture. The experiments were performed 3 times, 
with triplicates in each case. Data is expressed as mean values + SEM and significance differences are indicated in the figure. GC = glioma 
cells, MC = LAD2 cells, GCMC = glioma cells co-cultured with LAD2 cells, MCGC = LAD2 cells co-cultured with glioma cells. ns = not 
significant, *p < 0.05, **p < 0.01 versus cells grown without co-culture.
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aggressive phenotypes of the glioma cells through 
autocrine signaling pathways [26]. Also serglycin both 
from the glioma cells and MCs, via its interaction with 
CD44, can enhance growth, survival and differentiation of 
the cancer cells. CD44 is a versatile multifunctional cell 
surface glycoprotein involved in a variety of biological 
properties and physiological activities of cells. Its binding 
mechanism has been mostly noted in context to HA and the 
associated GAGs. Serglycin has been reported as a novel 
ligand for CD44 [37], and to the best of our knowledge 
is the only likely candidate of all MC mediators that can 
directly bind to CD44. 
MCs express a plethora of various receptors e.g. 
members of the CXCL10/CXCR3 and CXCL12/CXCR4 
family, which upon binding to its ligand can activate 
MCs [38]. Expression analysis of cytokines secreted by 
glioma cells co-cultured with MCs, revealed a significant 
increase in expression of CXCL10, CXCL12 and TNF-α. 
CXCL10 induces a wide spectrum of physiological and 
pathological effects including chemotaxis, induction of 
apoptosis, regulation of cell growth and mediation of 
angiostatic effects via the CXCR3 receptor, resulting 
in immune dysfunction, tumor development, metastasis 
and dissemination. Furthermore, the CXCL12/CXCR4/
CXCR7 axis has been implemented in carcinogenesis 
and tumor progression [27]. TNF-α, which has been 
shown to be involved in malignant diseases [39], had 
increased expression in the co-cultured glioma cells, 
which in turn can bind to its receptor on the MCs to 
activate them, thereby expanding the inflammatory 
network and facilitating proper establishment of the 
malignancy.
Figure 6: Serglycin can induce aggressiveness and propagation in glioma cells. (A) Immunohistochemical staining for ZEB-1 
in high-grade human glioma TMAs. Representative high-grade glioma TMA core (upper left panel) and selected magnified area (upper 
right panel) showing ZEB-1 expression and quantification of the ZEB-1 expression level (lower panel). HGG TMAs included tumor 
tissue from high-grade gliomas (anaplastic gliomas and glioblastomas, n = 101). Scale bar = 200 μm. (B) ZEB-1 expression levels 
positively correlates to the serglycin expression levels in high-grade glioma (Pearson correlation ρ < 0.01). (C) Expression analysis for 
ZEB-1, vimentin and Ki67 in the glioma cells after co-culture with LAD2 cells for 48 hours.  All the results are represented as increase 
in fold expression compared to the expression levels without co-culture. The experiments were performed 3 times, with triplicates in 
each case. Data is expressed as mean values + SEM and significance differences between GC+MC and GC are indicated in the figure. 
*p < 0.05, **p < 0.01 versus cells grown without co-culture. LGG = low-grade glioma, HGG = high-grade glioma. GC = glioma cells, 
GC+MC = glioma cells co-cultured with LAD2 cells. 
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We also observed an increase in IL-6 and CXCL1 
expression in MCs co-cultured with glioma cells. IL-6 
secreted in the TME has been suggested to promote 
development and progression of certain cancers by driving 
progression and EMT [32]. Dysregulated expression of 
CXCL1 and IL-6 have also been attributed to enhanced 
angiogenesis and tumorigenesis in cancer cells via 
constitutive activation of NF-κB [40]. Moreover, several 
cytokines and growth factors including CXCL1 and IL-6 
have been shown to exert their effect via their ability to 
bind to serglycin [15]. In this case serglycin acts as the 
modulator supplying an ECM microenvironment platform 
for exerting eventual effects.
Investigation of markers related to cancer 
progression in glioma cells co-cultured with MCs show a 
significant induction of ZEB1 and vimentin accompanied 
by a positive induction of glioma cell proliferation in 
co-culture with MCs. An increase in ZEB1 expression 
was also detected in human high-grade glioma TMAs. 
Statistical analysis of the expression of serglycin and 
ZEB1 in high-grade glioma showed a positive correlation. 
Our previous studies demonstrated a positive correlation 
between MC infiltration and the grade of glioma. Hence 
we believe that MC infiltration in high-grade glioma tissue 
can induce the aggressiveness of the glioma cells even 
further presumably as orchestrated by serglycin.
In conclusion, we showed elevated expression of 
serglycin in a large cohort of human high-grade glioma 
TMAs and demonstrated a correlation between glioma 
grade and serglycin expression level. We identified 
a positive correlation between serglycin expression 
and MC numbers. In line with these findings, in vitro 
analysis of patient-derived GBM cell lines co-cultured 
with MCs showed an induction of serglycin expression 
in glioma cells. This was accompanied by an increase of 
proinflammatory cytokines and markers related to cancer 
progression. Hence we conclude that serglycin acts both 
as a modulating factor as well as one of the contributing 
factors in MC – glioma cell crosstalk. The present study 
provides evidence that serglycin can serve as a potential 
prognostic marker and has detrimental effects in MC 
infiltrated glioma microenvironment that requires further 
mechanistic investigations.
MATERIALS AND METHODS
Cell cultures and tissue microarrays
All cells were cultured at 37°C under 5% CO2. 
U2987MG, a human glioma cell line [41], was cultured 
in 10% FBS-containing MEM supplemented with 4mM 
L-glutamine, 100 units/ml penicillin and 0.1mg/ml 
streptomycin. The U2987MG cell line was established from 
a patient with high-grade glioma [41] and was denoted as 
primary culture 18. This cell line has then been very well 
studied [42, 43] and subsequently established as a stable 
glioma cell line. Other glioma cell cultures used in this 
study are derived from patients diagnosed with primary 
GBM and are part of the Uppsala University Human 
Glioma Cell Culture (HGCC) collection that comprises well 
characterized GBM-derived cell cultures [19]. U3017MG, 
U3084MG, U3086MG, U3039MG, U3042MG, U3035MG, 
U3071MG, U3078MG, U3054MG, U3047MG, U3117MG 
and U3019MG cells were cultured on laminin (10 mg/ml) 
in serum-free (stem cell) conditions, to enrich for stem-like 
glioma cells, as described previously [44].
The human MC line LAD2 (obtained from Prof 
Dean Metcalfe at NIH/NIAID, MD, USA) was cultured 
as described previously [45] in StemPro medium 
supplemented with 4 mM L-glutamine, 100units/ml 
penicillin and 0.1mg/ml streptomycin and 100ng/ml SCF 
(Invitrogen, Carlsbad, USA).
Tissue microarrays (TMAs) and slide scanning were 
performed using the strategies of The Human Protein 
Atlas project (www.proteinatlas.org) [46, 47]. TMAs 
involved tumor tissue from high-grade gliomas (anaplastic 
gliomas and glioblastomas, n = 101) and gliomas WHO 
grade II [25] (astrocytomas, oligoastrocytomas and 
oligodendrogliomas grade II, n = 87).
Co-culture assays
To examine the effect of MCs on GBM cell 
growth and secretion, LAD2 cells were co-cultured in 6 
well format transwells (0.4µm) with the various HGCC 
cell lines for 24, 36 and 48 hours. Briefly, the glioma 
cell lines were plated on laminin (10mg/ml) coated 6 
well plates in serum-free (stem cell) conditions without 
growth factors and allowed to attach for 2–3 hours. For 
immunofluorescence staining laminin coated coverslips 
in 24 well plates were used for plating the glioma cells. 
Overnight SCF starved LAD2 cells were resuspended in 
normal growth medium without SCF (5 × 105 cells/ml) and 
added to the transwell. The co-cultures were left to grow 
for 24, 36 and 48 hours. After the stipulated time-points 
the LAD2 cells were collected from the transwell and 
the cell-pellet was used for further analysis. The glioma 
cell lines were detached by Accutase. The cell pellet was 
washed in ice-cold PBS and then stored in −20°C and 
used for further analysis. When grown on coverslips, the 
glioma cells were washed with PBS followed by 3% PFA 
fixation for 10 min. Stimulation experiment was done in 
triplicates. Appropriate negative controls were kept for 
each experiment. 
RNA extraction, cDNA synthesis and qPCR
RNA was extracted from control LAD2 and control 
glioma cells as well as from LAD2 and glioma cells after 
co-culture. RNA extraction was done using GENEJET 
RNA Purification Kit (Life Technologies, Waltham, 
MA) extraction method from cell pellets. cDNA was 
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synthesized using the High Capacity RNA-to-cDNA™ 
Kit (Thermo Fisher Scientific, Waltham, MA) which 
was then used to perform the qPCR using the PowerUp 
SYBR Mastermix (Table 1). For all qPCR analysis, ß-actin 
expression was used as endogenous control. Results are 
then calculated as increase in fold expression of the co-
cultured cells compared to the expression levels without 
co-culture. The experiments were performed 3 times, with 
triplicates in each case.
Immunohistochemistry and immunofluorescence
TMAs involved tumor tissue from high-grade 
gliomas (anaplastic gliomas and glioblastomas, 
n = 101) and gliomas WHO grade II [48] (astrocytomas, 
oligoastrocytomas and oligodendrogliomas grade II, 
n = 87). For immunohistochemical analysis, primary 
antibodies directed against human MC tryptase, hTPS 
(sc-33676, Santa Cruz Biotech, Santa Cruz, CA, USA), 
CD163 (HPA051974, Atlas Antibodies, Stockholm, 
Sweden), Serglycin (HPA000759, Atlas Antibodies, 
Stockholm, Sweden) and ZEB-1 (AMAb90510, Atlas 
Antibodies, Stockholm, Sweden) were used. Briefly, 
slides of tissue samples were deparaffinized in xylene, 
rehydrated in a series of aqueous solutions with decreasing 
concentrations of ethanol, boiled (125°C, 4 min) in 
epitope retrieval buffer (Thermo Scientific, Waltham, 
USA) in a pressure boiler and subsequently cooled for 
30 min. Immunohistochemistry was then performed 
using the Autostained 480 instrument (Lab Vision, 
Freemont, USA) with 3′3′-diaminobenzidine (DAB) as a 
substrate. Thereafter, the slides were counterstained with 
hematoxylin, mounted and scanned using the ScanScope 
XT system (Aperio Technologies, Vista, USA).
Tissue microarrays preparation (TMAs), 
immunohistochemistry (IHC) and slide scanning were 
performed using the strategies of The Human Protein Atlas 
project (www.proteinatlas.org) [46, 47]
Immunofluorescent staining was carried out using 
primary antibodies against human CD3 (A0452, Dako, 
Agilent Technologies, CA USA), human CD8 (M7103, 
Dako, Agilent Technologies, CA USA) and Serglycin 
(sc-393521, Santa Cruz Biotech, Santa Cruz, CA, USA). 
Alexa 488 or Alexa 555 (Invitrogen, Carlsbad, USA) was 
used as secondary antibody. Briefly, deparaffinization was 
performed for the TMAs, whereas for staining of the cells 
a 10 minutes fixation in 4% PFA was performed. Then the 
slides were rinsed in PBS, blocked in 5% NGS in PBS-T 
(supplemented with 0.2% Triton-X 100 (Sigma Aldrich, 
St Loius, USA)) for 1 hour, followed by overnight 
incubation (4°C) with the primary antibody diluted in 
the blocking solution. The slides were subsequently 
incubated with appropriate secondary antibody for 45 
min. Nuclei was stained with DAPI (1:5000) for 15 min 
and mounted in Immu-mount (Vecta Labs, Vector Labs, 
Burlingame, CA)
Image analysis
Immunohistochemically stained TMA slides 
were scanned as described previously [47]. Slides with 
immunofluorescence staining were imaged using ZEISS 
AxioImager. Image analysis was done using ImageJ 
software.
Bioinformatic analysis
Survival analysis was done using the TCGA 
GBM data downloaded from the cBio and TCGA 
portals. SERGLYCIN (SRGN) TCGA expression data 
(TCGA provisional, Affymetrix GeneChip Human 
Genome U133 Plus 2.0 Array, for 540 patients) [49] 
was downloaded from the cBio Portal (http://www.
cbioportal.org/). Clinical data for these patients with 
primary GBM was obtained from the TCGA portal 
and in each case the maximum value of the survival 
times reported for a patient was used. Clinical data for 
comparing SRGN expression across different tumors 
was downloaded and statistically analyzed using the 
R2: Genomics Analysis and Visualization Platform 
(http://r2.amc.nl) and in each case datasets with large 
set of patient material was used. Transcriptome data 
for the HGCC collection was generated on Affymetrix 
GeneChip Human Exon 1.0 ST Arrays, RMA normalized 
and transformed to z-scores. HGCC cell lines were 
classified based on their expression profile for known 
signature genes [50] using known TCGA subtypes 
as reference and a k-nearest neighbour algorithm as 
described elsewhere [19].
Statistical analysis
Statistical analyses were done using the Graphpad 
Prism software (GraphPad Software 6.0d) and R [51]. For 
group-wise comparisons the Student’s unpaired t-test was 
used. For comparisons between more than two groups, 
one-way ANOVA tests were applied. Kaplan-Meier 
survival analysis was used for the TCGA and HGCC 
data and was performed with censoring at confidence 
interval 95%. The statistical significance of any observed 
survival difference was determined using the log-rank 
test. Correlation analyses employed Pearson coefficient 
analysis.
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